Ovarian Cancer: Clinical Trials and Research

Ovarian cancer lab researcher

Because early symptoms of ovarian cancer are few and nonspecific, most cases are found at an advanced stage. Due to the complex biology of the disease, the development of effective medications has been particularly challenging for scientists. For these reasons, the ovarian cancer team at the University of Chicago Medicine integrates medical care with ongoing clinical, basic and translational research. Truly comprehensive care offers patients the most advanced treatments and technologies but also asks questions that may lead to the next novel therapies. Our goal is to better understand the disease while providing optimum care for our patients.

Clinical Trials

Allison Sharpe Allison Sharpe enrolled in a clinical trial for ovarian cancer. Sharpe is an energetic advocate for awareness of the disease and a mentor to other patients.

Our ovarian cancer physician/scientists are members of the internationally recognized University of Chicago Comprehensive Cancer Center (UCCCC), an NCI-designated cancer research center. As part of this consortium of select cancer research centers, our program -- and our patients --have access to emerging therapies and the highest level of care for ovarian cancer. This includes Phase 1 clinical trials, the earliest study of new medications or protocols typically available in just a few centers.

»Learn about current clinical trials for ovarian cancer at the University of Chicago Medicine
»Learn more about clinical trials at the University of Chicago Medicine

The ovarian cancer program is also a lead site for the Gynecologic Oncology Group (GOG), a National Cancer Institute (NCI) supported cooperative group that develops and runs leading clinical trials in the field of gynecologic cancers. In 2014, the University of Chicago’s cooperative clinical trials group, which includes the GOG, was awarded a U10 grant. This prestigious award recognizes the significant expertise of our cancer center as a lead academic site for clinical trials.

Research

Ernst Lengyel, MD, PhD Ernst Lengyel, MD, PhD

The University of Chicago Medicine is home to a large ovarian cancer research laboratory led by Ernst Lengyel, MD, PhD. It is dedicated to improving the understanding of the biology of ovarian cancer metastasis and to exploring new drugs for its treatment. The scientific work is integrated into the clinical care we offer to women with this disease. In recent years, researchers in the lab published their findings in leading scientific journals, characterized two new targets in ovarian cancer that led to clinical trials, and developed a novel method to find new drugs. »To learn more, visit Dr. Lengyel's research website

Ovarian cancer research at the University of Chicago Medicine focuses on:
Drug discovery -- Joining forces with other research centers across the country, our physician-scientists are actively trying to find novel drugs and determine which drug combinations can be given at effective doses while causing the fewest side effects.

Understanding tumor spread (metastasis) -- Characterizing tumors as well as examining the early steps in how ovarian cancer spreads, or metastasizes, to other parts of the body.

Imaging -- Exploring new imaging agents for early detection of ovarian cancer. This effort is an extension of other collaborative work with University of Chicago biochemists that recently resulted in a promising method for more precisely differentiating malignant and benign tissue in early ovarian cancer.

Ovarian cancer prevention -- Evaluating the anti-cancer effects of commonly used medications and translating research findings into clinical trials.

Ovarian cancer lab researcher looking into microscope

Genetic and protein studies -- Understanding the changes in genes and proteins that underlie the first steps of ovarian cancer development. The ovarian cancer research team worked with the University of Chicago Medicine Department of Pathology in developing a program to collect and store tissue, blood and DNA samples from patients with ovarian cancer.